Proactive Investors - Run By Investors For Investors

Rhinomed wins FDA approval for nasal dilator

Rhinomed wins FDA approval for nasal dilator

Rhinomed's (ASX:RNO) sport technology the Turbine was granted registration with the US Food and Drug Administration as a medical device.

The Turbine™ is an internal nasal dilator that increases airflow by an average of 38% and can assist athletes as a solution to breathlessness during aerobic exercise.

A recent independent high performance product trial was carried out by former Olympic Cyclist, Rob Crowe, which showed that 66% of professional riders increasing their power output at an average of 6.5%.

Successfully granting US FDA registration of the Turbine is an important step in allowing the Turbine™ to enter the giant US market with premium positioning as a FDA class 1 medical device in the US.

The Turbine is currently sold on line and at selected retail outlets in Australia.

Registration granted to the Turbine by the US FDA allows the company to have a much wider range of discussions with US based retailers and wholesalers.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full RNO profile View Profile

Rhinomed Ltd Timeline

September 15 2015

Related Articles

seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use